Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
467,848

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for AMED

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Amedisys, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 139 54 46 83 96
Receivables 313 297 275 255 238
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 45 38 36 23 16
Total Current Assets 497 389 357 362 351
Net Property & Equipment 42 16 18 24 28
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 48 21
Intangibles 1,347 1,389 1,307 1,007 723
Deposits & Other Assets 85 80 73 33 55
Total Assets 2,060 1,976 1,857 1,567 1,263
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 28 44 38 43 31
Current Portion Long-Term Debt 36 16 13 11 10
Current Portion Capital Leases 26 0 0 0 0
Accrued Expenses 277 263 292 313 258
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 106 0 0 60 0
Total Current Liabilities 474 356 374 456 327
Mortgages 0 0 0 0 0
Deferred Taxes/Income 41 20 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 362 419 432 205 232
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 1 5 5 34 6
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 940 870 881 756 621
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 787 755 728 698 645
Retained Earnings 748 758 639 430 246
Other Equity 53 55 45 2 1
Treasury Stock 469 461 436 319 251
Total Shareholder's Equity 1,120 1,107 976 811 642
Total Liabilities & Shareholder's Equity 2,060 1,976 1,857 1,567 1,263
Total Common Equity 1,120 1,107 976 811 642
Shares Outstanding 32.60 32.40 32.60 32.80 32.20
Book Value Per Share 34.35 34.15 29.95 24.72 19.92

Fiscal Year End for Amedisys, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 157 121 139 94
Receivables NA 357 359 313 320
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 42 46 45 54
Total Current Assets NA 556 526 497 467
Net Property & Equipment NA 45 43 42 40
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 1,346 1,346 1,347 1,348
Deposits & Other Assets NA 87 86 85 84
Total Assets NA 2,117 2,090 2,060 2,027
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 27 36 28 35
Current Portion Long-Term Debt NA 38 37 36 35
Current Portion Capital Leases NA 0 0 26 0
Accrued Expenses NA 283 279 277 266
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 106 106 106 106
Total Current Liabilities NA 480 485 474 468
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 47 43 41 35
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 351 356 362 367
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1 1 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 938 947 940 934
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 803 795 787 777
Retained Earnings NA 795 762 748 729
Other Equity NA 54 54 53 54
Treasury Stock NA 473 469 469 466
Total Shareholder's Equity NA 1,179 1,143 1,120 1,094
Total Liabilities & Shareholder's Equity NA 2,117 2,090 2,060 2,027
Total Common Equity 0 1,179 1,143 1,120 1,094
Shares Outstanding 32.70 32.70 32.60 32.60 32.60
Book Value Per Share 0.00 36.05 35.05 34.35 33.54